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The thrombin-like enzyme from Bothrops barnetti named barnettobin was puriﬁed. We report some
biochemical features of barnettobin including the complete amino acid sequence that was deduced from
the cDNA. Snake venom serine proteases affect several steps of human hemostasis ranging from the
blood coagulation cascade to platelet function. Barnettobin is a monomeric glycoprotein of 52 kDa as
shown by reducing SDS-PAGE, and contains approx. 52% carbohydrate by mass which could be removed
by N-glycosidase. The complete amino acid sequence was deduced from the cDNA sequence. Its sequence
contains a single chain of 233 amino acid including three N-glycosylation sites. The sequence exhibits
signiﬁcant homology with those of mammalian serine proteases e.g. thrombin and with homologous
TLEs. Its speciﬁc coagulant activity was 251.7 NIH thrombin units/mg, releasing ﬁbrinopeptide A from
human ﬁbrinogen and showed deﬁbrinogenating effect in mouse. Both coagulant and amidolytic ac-
tivities were inhibited by PMSF. N-deglycosylation impaired its temperature and pH stability. Its cDNA
sequence with 750 bp encodes a protein of 233 residues. Indications that carbohydrate moieties may play
a role in the interaction with substrates are presented. Barnettobin is a new deﬁbrinogenating agent
which may provide an opportunity for the development of new types of anti-thrombotic drugs.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
Venoms of several snake species contain abundant active pro-
teases and peptides that cause changes in the hemostatic system of
human victims or experimental animals by a variety of mecha-
nisms. One group of pharmacologically useful venom components
is the serine proteases (SVSPs) which are widely distributed in the
venoms of the snake families Viperidae, Elapidae and Colubridaerom Bothrops barnetti; DL-
, p-nitroanilide; TAME, Na-
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son SAS. All rights reserved.[1]. SVSPs belong to the clan PA, subclan S and the trypsin family S1
[2]. They display quite diverse substrate speciﬁcity. Due to their
versatility of pharmacological action, these enzymes affect the
blood coagulation cascade, the ﬁbrinolytic, kallikrein-kinin system,
endothelial cells and platelet function [1,3], and play key roles in
hemorrhage and blood clotting disorders [4]. Since the ﬁbrinogen
clotting (TLE) enzymes bring about clotting in vitro but anti-
coagulation (deﬁbrination) in vivo, they are intermediate between
true coagulants and anticoagulant factors [5,6]. The SVSPs that have
been sequenced show high homologies in the primary structure,
particularly in the region surrounding the catalytic site, however,
they are quite speciﬁc toward a given macromolecular substrate. A
subgroup of SVSPs, the so-called TLEs, contain endopeptidases
which possess primarily one of the essential functions of thrombin:
the clotting of ﬁbrinogen (Fg) [7]. The ability to clot blood is due to
the direct action of the venom TLEs on the Fg components of the
blood. Some of them can hydrolyze Fg speciﬁcally and release
ﬁbrinopeptide A or B or both [7]. In addition, the TLEs do not
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not cross-linked and is readily degraded by the ﬁbrinolytic system.
These remarkable properties enable their clinical use as deﬁb-
rinogenating agents [6,8]. These enzymes are deﬁned by a common
catalytic mechanism, that includes a highly reactive serine residue
that plays a key role in the formation of a transient acyl-enzyme
complex, which is stabilized by the histidine and aspartic residues
within the reactive site [9]. The active site serine also reacts with
amides, esters and peptides, and is sensitive to inhibition by serine-
modifying reagents PMSF and DFP. Due to their therapeutic value,
some of these enzymes have been used as anti-thrombotics to
facilitate tissue oxygenation and prevent arterial embolism [3,4,10],
and are widely used in laboratories in the detection of Fg in hep-
arinized blood and as a reagent in coagulation studies [11,12].
Furthermore, thrombin inhibitors like anti-thrombin-III (AT-III),
hirudin and heparin usually do not inhibit TLEs.
Bothrops barnetti (Barnett’s Lancehead) is an endemic venomous
pit viper native to the Paciﬁc coast of northern Perú and the south
east of Ecuador. Its habitats are low elevations in arid to semi-arid
tropical scrub [13]where it is themain poisonous snake responsible
for human accidents [14]. Although B. barnetti is recognized as a
medically relevant species in the Paciﬁc coast of northern Perú,
there are only scattered reports on the identiﬁcation and charac-
terization of active venom components involved in local and sys-
temic pathological effects. Recently, the protein composition as
well as the main pharmacological properties of B. barnetti’s venom
in comparison with the venoms of two other Peruvian pit vipers of
medical importance Bothrops atrox and Bothrops pictus has been
reported by our group [15]. The venom of B. barnetti contains large
amounts of metalloproteases, SVMPs, (74.1%) including P-I class
SVMPs comprises only a metalloproteinase domain (23 kDa) and by
the multidomain P-III class comprises metalloproteinase domain,
disintegrin-like domain and cysteine rich domain (55 kDa),
respectively and 6.7% serine proteases among other venom com-
ponents [15]. Thus, its venom presents a toxicological proﬁle
similar to those of other Bothrops sp. venoms in Latin America.
The present study aims to determine the structural and func-
tional characterization of a novel TLE (Bb-TLE), termed barnettobin
from the B. barnetti venom. Analysis of a cDNA, encoding barnet-
tobin as well as the deduced amino acid sequences is discussed. We
show that barnettobin is a ﬁbrinogenolytic enzyme and that its
carbohydratemoieties play an important role in its interactionwith
substrates and the protection of its catalytic activities.
2. Materials and methods
2.1. Materials
Bovine thrombin, PNGase F, and o-glycosidase, human ﬁbrin-
ogen essentially plasminogen free, ﬁbrinopeptides A and B, DL-
BAPNA, TAME, S-2251 were obtained from Sigma Chemical Co.
(St. Louis MO, U.S.A.). All other chemicals were of analytical reagent
grade.
2.2. Puriﬁcation of barnettobin
Barnettobin was isolated from B. barnetti venom by size exclu-
sion on Sephadex G-100, ion exchange on CM Sephadex C-50 and a
second Sephadex G-100 chromatography. Fractions were analyzed
by SDS-PAGE and for enzymatic activity by using DL-BAPNA and Fg
as substrates. Approx. 319 mg of crude venomwas dissolved in 3 ml
of 50 mM ammonium acetate buffer, pH 5, and centrifuged at 3000
g. The supernatant solution (300 mg protein) was loaded onto a
Sephadex G-100 column (1.4 64 cm) equilibrated and eluted with
the above buffer at 14 ml/h. Fractions containing the Bb-TLE(w52 kDa protein revealed by SDS-PAGE) were collected and
concentrated to1.2 ml with an Ultracell Centrifugal Filter Unit
(Amicon), then this material (105.8 mg) was applied to a CM
Sephadex C-50 column (1.2  45 cm) equilibrated with the above
buffer and eluted with a linear gradient of 0.1-1 M NaCl in the same
buffer at 14 ml/h. Active fractions containing Bb-TLE were collected,
concentrated (1 ml, 6.4 mg protein) and re-chromatographed on a
Sephadex G-100 column (1  30 cm) equilibrated and eluted with
50 mM ammonium acetate buffer, pH 5.
Protein concentration was determined by BCA protein assay
(Pierce Chemical, USA). Anti-barnettobin antiserumwas raised in a
rabbit (New Zealand 2.5 kg) as described in Ref. [16]. The IgG
fraction of immune rabbit serum was puriﬁed by afﬁnity chroma-
tography on protein A Sepharose.
2.3. Assay of ﬁbrinopeptides release
Fibrinopeptides (FPs) were generated by incubation of 4 mg of
Bb-TLE with 1.0 ml of human Fg (3.5 mg/ml) in 50 mM Tris-HCl
buffer, pH 7.4, containing 70 mM NaCl at 37 C for 1.0, 10, and
20 min. Insoluble proteins were removed with 2% TCA and the
supernatants were subjected to reverse phase HPLC on an analyt-
ical column (4.6 mm  250 mm) of Vydac C18 (218TP54) using a
linear gradient (0e15%, v/v, during 15 min; then 15e30% during a
further 60 min) of acetonitrile in 0.1% TFA. The times of elution of
FPA and FPB were determined by passing controls samples of hu-
man FPs A and B (Sigma) through the column as described [17].
2.4. Gel electrophoresis
SDS-PAGE without or after reduction with 4% b-mercaptoetha-
nol was carried out according to Laemmli [18], using 10 or 12% gels
and stained with coomassie blue R-250. The relative molecular
mass (Mr) of the isolated protease was estimated from reducing
gels by comparison with a protein calibration mixture consisting of
bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic
anhydrase (29 kDa), and lysozyme (14.3 kDa).
2.5. N-terminal sequence determination
The amino terminal amino acid sequence of the S-pyridyl-
ethylated intact Bb-TLE (100 mg) was determined by Edman
degradation using a Shimadzu PPSQ-21A automated protein
sequencer as described [17].
2.6. MALDI-TOF mass spectrometry
Protein masses were determined by Matrix assisted laser
desorption/ionization time-of- ﬂight (MALDI-TOF-TOF) mass spec-
trometry. Spectra were recorded and analyzed using a Bruker
Autoﬂex III Smartbeam instrument in a linear positive mode
controlled by the proprietary COMPASS 1.2, as described in a
previous report [16].
2.7. Deglycosylation of the native barnettobin
50 mg of barnettobin was dissolved in 50 ml of denaturing buffer
(0.5% SDS, 1% b-mercaptoethanol). The sample solution was dena-
tured by boiling for 5 min. After addition of 50 ml of reaction buffer
(50 mM Tris-HCl, pH 8.0), 2.5 ml of detergent solution (IGEPAL 15%,
Roche) and 2 units of recombinant PNGase F or o-glycosidase, the
samples were incubated for 24 h at 37 C. The reaction was
terminated by boiling for 5 min and PAGE loading buffer was added
to the reactionmixture. The native and the deglycosylated enzymes
were analyzed by SDS-PAGE after reduction as described above. In
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deglycosylated under non denaturing conditions, by incubating the
enzyme with PNGase F without the addition of denaturing and
reducing agents for 48 h according to [19].
2.8. Enzymatic activity
The Bb-TLE was assayed for its clotting activity in vitro or by its
amidolytic activity. Amidolytic activity of the Bb-TLE was routinely
determined using the substrate DL-BAPNA at 37 C in 50 mM Trise
HCl buffer, pH 8.0 following the increase in absorbance at 405 nm
per unit of time at 37 C. Clotting activity was measured by mixing
appropriate concentrations of the samples (0.5e2.4 mg) with
0.98 ml of Fg (3.5 mg/ml) in 100 mM Tris-HCl buffer, pH 7.4, con-
taining 1 mM CaCl2 at 37 C. One unit of coagulant activity was
considered to be equivalent to one NIH thrombin unit. Speciﬁc
activity was deﬁned as the number of NIH thrombin units per 1 mg
enzyme.
2.9. Determination of procoagulant and deﬁbrinogenating activities
Procoagulant activity was measured by in vitro determination of
the minimum coagulant dose (MCD) using either a solution of
bovine Fg and named (MCD-F) or a standard citrated solution of
human plasma (MCD-P), according to [20]. To estimate the mini-
mum deﬁbrinogenating dose (MDD), the whole blood clotting
assay (MDD-WBC) was used. The MDD-WBC was deﬁned as the
minimum dose of Bb-TLE that produced non-clotting blood within
60 min of intravenous injection [20]. The deﬁbrinogenating activity
was evaluated in adult mice (CF strain, 20e22 g). Animals were
randomly assigned to form six groups (four animals per group).
Doses of barnettobin (50, 25, 12.5, 6.0, 3.0, 1.0 mg/22 g mouse) in
0.1 ml of saline solution (89% NaCl) were injected into the tail vein
according to [20]. The experiments reported herewere done within
the guidelines established by the Brazilian College for Animal
Experimentation and overseen by FUNED Animal Ethics
Committee.
2.10. Digestion of ﬁbrin(ogen)
Fibrino(geno)lytic activity was measured as described in the
previous report [21] as follows: 0.1 ml of Fg (3 mg/ml) in 50 mM
Tris-HCl (pH 7.4) buffer was incubated with 9.6 nM barnettobin at
37 C for 15, 30, 60 and 120 min. The digestions were stopped by
adding SDS-PAGE sample buffer and heated at 100 C for 3 min. The
reaction mixtures were analyzed by SDS-PAGE (12% gel).
2.11. Stability assays
pH and temperature effects on amidolytic and coagulant activ-
ities were conducted at pH values ranging from 2 to 10, and at
different temperatures from 20 to 100 C. The following buffers
(200 mM) were used in the reactions: sodium acetate buffer (pH
2.0e4.0), sodium phosphate buffer (pH 6.0e7.0), Tris-HCl buffer
(pH 8.0e10.0). All buffers contained 0.15 M NaCl to maintain con-
stant ion strength. To assess the temperature stability, the Bb-TLE
was incubated at temperatures between 20 and 100 C. The enzyme
was used with a ﬁnal concentration of 0.2 mM throughout all the
assays. TriseHCl buffer (50 mM, pH 7.4) was used as the solvent for
the estimation of the optimum temperature.
2.12. Inhibition studies
The effects of several protease inhibitors on the puriﬁed enzyme
were examined by determining its activity on DL-BAPNA. Puriﬁedenzyme (1 mg) was pre-incubated with PMSF, EDTA, TLCK, and DTT
(5mM each), SBTI (200 mg/ml), chymostatin (50 mM) and heparin (5
units) in 50 mM Tris-HCl buffer, pH 7.5, for 15 min at 37 C. The
mixtures were subjected to amidolytic assay as described above.
2.13. Synthesis and sequencing of cDNA
For this study a juvenile (female) specimen of B. barnetti
captured near the arid locality of Chiclayo in the department of
Lambayeque, north of Perú was maintained in the serpentarium of
the Instituto Nacional de Salud (INS, Lima-Perú). Venom was ob-
tained by manual compression of the venom glands. 500 ml of fresh
venom collected in a sterile vial free of DNAses and RNAses was
frozen immediately. Two primers were designed on the basis of the
highly conserved cDNA sequences encoding batroxobin (J02684.1),
bothrombin (AB178321.1), BjussuSP-I (AY251282.1), Bothrops insu-
laris-TLE, BITS01A (AF490536.1), Bothrops asper-TLE (DQ2447724.1)
and Gloydius ussuriensis-TLE (AF336126.1) and synthesized (Invi-
trogen Custom Primers). For extraction and puriﬁcation of mRNA
the kit Total RNA Puriﬁcation (Amresco), and for synthesis of the
complement cDNA, the kit Transcriptor First Strand cDNA Synthesis
(Sigma) were used in accordance with the manufacturer’s in-
structions. To amplify the gene of barnettobin the kit Master Mix
Platinum Taq DNA Polymerase (Invitrogen) was used according to
the manufacturer’s instructions. Sequencing of the ampliﬁcation
products was performed on an ABI 3730 XL automated sequencer
(Macrogen, Inc, South Korea). Both the cDNA and deduced protein
sequences were compared with other sequences deposited in
GenBank and SwissProt.
2.14. Immunoblot and enzyme-linked immunoabsorbent assay
(ELISA)
For analysis of the immunological reactivity of several TLEs from
pit viper venoms against the anti-Bb-TLE-IgG, immunoblotting and
ELISA were performed. Samples for immunoblot analysis were
subjected to reducing SDS-PAGE (12% gel), followed by transfer to
nitrocellulose membrane in accordance to the manufacturer’s (Bio
Rad Laboratories) instructions. Blotting procedures, using rabbit
IgG (4 mg) against Bb-TLE were conducted as described [16]. For
ELISA, multiwell plates were coated overnight with 0.5 mg/well of
each antigen (TLEs of B. barnetti, B. leucurus, B. atrox, Lachesis muta
muta and Crotalus durissus terriﬁcus) in 50 mM carbonate buffer, pH
9.6. After washing with 0.05% Tween-saline, a blocking solution (2%
casein in phosphate buffered saline, PBS) was added (1 h at room
temperature). After two additional washing steps with the same
solution, anti-Bb-TLE IgG diluted in PBS containing 0.25% casein and
0.05% Tween 20 was incubated for 1 h at 37 C. After six washes,
peroxidase-coupled anti-rabbit IgG (Sigma, diluted 1:12,000) was
added and incubated 1 h at room temperature. The wells were
washed and 100 ml of peroxidase substrate o-phenylenediamine
(0.33 mg/ml in citrate buffer, pH 5.2 in the presence of 0.03%
hydrogen peroxide) was added and the color reaction was run for
15 min at 37 C in the dark. The reaction was stopped by adding
20 ml of a 1:20 dilution of sulfuric acid. Absorbance was read at
492 nm.
2.15. Phylogenetic tree of serine proteases and 3D model of
barnettobin
The three dimensional structure of barnettobin was obtained
with the Pymol program, using the structure of TSV-PA (PDB 1BQY)
as a templete [22]. In order to analyze the evolutionary relationship
among thrombin, trypsin, and the SVSPs, a phylogenetic tree was
Table 1
Puriﬁcation of Bb-TLE from B. barnetti venom.
Steps Protein mg recovery (%) Clotting activitya Amidolytic activityb
Total NIH units Speciﬁc units/mg P.F.c Total U Speciﬁc U/mg P.F.c
Crude venom 300 100 2700 9 1 8.078 0.027 1
Sephadex G-100 106 35 3150 30 3 8.019 0.076 2.8
CM-Sephadex 6.4 2 838.4 131 14.5 4.847 0.755 28
C-50
Sephadex G-100 1.8 0.6 460.3 257 28.5 2.519 1.407 52
a One unit of coagulant activity on bovine Fg was considered to be equivalent to one NIH thrombin unit; speciﬁc coagulant activity was deﬁned as the number of NIH units
per mg.
b One unit of amidolytic activity was deﬁned as the amount of enzyme hydrolyzing 1.0 mmol of DL-BAPNA per min (at 37 C in Tris-HCl, buffer, pH 8.0).
c P.F. puriﬁcation factor.
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SVSPs of viperidae snakes using the program MEGA 4.1.2.16. Other assays
Hydrolysis of the synthetic peptides: thrombin substrate Glycyl-
Prolyl-Arginyl-4-pNA acetate (Chromozyn TH) was assayed ac-
cording to [23]. Esterase activity was tested on the TAME and
Benzoyl Arginil ethyl-ester (BAEE) substrates [24]. Plaminogen
activating activity was tested on plasmin substrate Val-Leu-Lys-
pNA (S-2251) as described [25]. All assays were conducted in
50 mM TriseHCl buffer, pH 8.0, containing 0.1 M NaCl at 37 C for
15 min. After the addition of enzyme (1 mg), product formationwas
followed by measuring the change in absorbance at 247 nm
(TAME), 253 nm (BAEE) and 405 nm (DL-BAPNA, chromozyn TH
and S-2251). The determination of activity is based on the differ-
ence in absorbance between the p-nitroanilide formed and the
original substrate. The increase in absorbance is proportional to the
enzymatic activity.
GenBank accession code of Barnettobin: JX499027.3. Results
3.1. Puriﬁcation of barnettobin
The puriﬁcation of the Bb-TLE (barnettobin) from B. barnetti
venom was achieved as summarized in Table 1. In the initial
Sephadex G-100 fractionation of the crude venom (300mg protein)
four peaks having absorbance at 280 nm were obtained (P1-P4)
(not shown). The Fg clotting and amidolytic activities were found in
peak 2 and were chosen for further puriﬁcation. In the second step,
puriﬁcation was carried out by ion exchange chromatography on a
column of CM Sephadex C-50. The active material from the pre-
ceding step (105.8 mg) was applied as described in Methods. Seven
peaks of absorbance at 280 nmwere obtained (P1-P7) (not shown).
The amidolytic activity that corresponds to clotting activity was
eluted in peak 6. Final puriﬁcation of barnettobinwas performed by
rechromatography on a Sephadex G-100 column as described in
Methods. From 6.4 mg protein in this step, 1.8 mg of protein was
obtained with a puriﬁcation factor of 25.7 and 52.2 based on clot-
ting and amidolytic activities, respectively (Table 1). In all puriﬁ-
cation steps it was observed that clotting and amidolytic activities
eluted in the same fractions. The homogeneity of the protease was
assessed by SDS-PAGE and reverse phase HPLC (not shown). As
shown in Fig. 1A, the puriﬁed enzyme gave a single protein band on
SDS-PAGE under both non-reduced (NR) or reduced (R) conditions.
The molecular mass of the protease was estimated to be about
52 kDa under reducing conditions. Barnettobin is a highly glyco-
sylated protein containing approx. 52% carbohydrate by mass, and
its apparent molecular mass was reduced to approx. 28 kDa afterdigestion with PNGase F (Figs. 1B and 2). Virtually all glycosylation
of the protease was shown to be due to N-linked sugar chains since
treatment with o-glycosidase did not affect the mobility of the
protein (Figs. 1B and 3). The Mr of native enzyme detected by mass
spectrometry was 39,077.948 (not shown). We could not obtain a
clear value for MHþ by MALDI TOF/TOF mass spectrometry analysis
of the intact protein, probably due to heterogeneity of the sugar
chains.
On the other hand, the N-terminal amino acid sequence of the S-
pyridyl-ethylated native protein was determined up to the 20th
residue as being VIGGDECDINEHPFLAFLYS (single-letter amino acid
code), which is identical to the deduced from the cDNA sequence
protein (Fig. 2).3.2. Nucleotide sequencing of the protease cDNA
In this study, we have used an alternative strategy [26] to obtain
cDNA from total RNA of snake venom. By using the RT-PCR 25 ng/ml
cDNAwas synthetized from 500 ml of fresh venom of one B. barnetti
specimen obtained as described in Materials and methods. As a
result, mRNA was obtained from fresh venom without sacriﬁcing
the snake. After cDNA ampliﬁcation a value of approx. 750 bp (not
shown) was found which codes for a primary structure of a protein
with 233 amino acid residues (Fig. 2). The complete amino acid
sequence of barnettobin predicted from the cDNA nucleotide
sequence was aligned with those of other SVSPs and was found to
be closely homologous with them (Fig. 3). All of the SVSPs
conserved the 12 cysteine residues paired in six disulphide bridges.
By comparison with other members of the SVSP family the amino
acid residues that are essential for serine proteases such as the
catalytic center triad His40, Asp85 and Ser179 (barnettobin
numbering), their ﬂanking sequences and the substrate-binding
Asp178 were found to be conserved in barnettobin, indicating
that the enzyme is a serine protease. In conﬁrming that the protein
is highly glycosylated, barnettobin was found to contain three po-
tential glycosylation sites, N-X-S/T, located at amino acid residues
129-131, 145-147 and 226-228 (Fig. 3).3.3. Fibrinogen clotting and release of ﬁbrinopeptides
We have tested the ﬁbrinogenolytic activity of barnettobin with
humanFg (plasminogen free) as substrate. The time-coursedigestion
of Fg andﬁbrin at 37 C by the puriﬁed enzyme (molar ratio enzyme:
Fg 1:976) at different time intervals of incubation was accompanied
by SDS-PAGE. Under our experimental conditions, the enzyme di-
gests the a chains of Fg and ﬁbrin time-dependently (Fig. 4A and B),
and does not require any other factors for this activity. No signiﬁcant
alterations in the electrophoretic mobility of Bb and g chains of Fg
could be detected even at 120 min incubation period. The puriﬁed
enzymewasable to clot humanFgwitha speciﬁc activityof 251.7NIH
Fig. 1. SDS-PAGE (12% gels) analysis of native and deglycosylated barnettobin. A, native enzyme under non-reducing (NR) and reducing (R) conditions; B, native enzyme control (1)
and after treatment with PNGase F (2) or with o-glycosidase (3). The gels were stained with coomassie blue. Marker proteins are indicated at left.
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batroxobin (210-230 NIH units/mg) from B. a. moogeni [17] and for
other TLEs e.g. leucurobin from B. leucurus [17]. RP-HPLC analysis of
Bb-TLE-treated human Fg supernatants after 0, 1, 10, and 20 minFig. 2. cDNA sequence and deduced amino acid sequence of barnettobin. The pre-
dicted amino acid sequence for barnettobin precursor protein is underlined and the
pro-peptide region is indicated by dotted line. The predicted amino acid sequence is
shown above; the numbering starts at the amino terminal amino acid of mature
protein (valine). Direct N-terminal sequence of the mature protein determined by
Edman degradation is in bold. The three potential N-glycosylation sites are in gray.incubation at 37 C are shown in Fig. 5, The retention times for
standard FPA and FPB are presented in panel A. The only detected
product being FPA and its phosphorylated derivative APare shown in
Fig. 5, panels C-D; essentially similar results to those after 10 min
digestion was obtained by RP-HPLC analysis of incubation mixture
for 20 min (not shown).
In connection with these results we have determined in vitro
theMCD-F/P of Bb-TLE and in vivo theMDD-WBC for the native and
deglycosylated enzyme. As can be seen in Table 4, the enzyme
exerted a direct thrombin-like effect on Fg and therefore also clots
human plasma. In addition, native Bb-TLE showed in vivo antico-
agulant activity as evaluated by the MDD-WBC; 1.1 mg/mouse failed
to clot blood within 60 min of i.v. injection. However, deglycosy-
lated Bb-TLE loses its clotting and deﬁbrinogenating effects.
3.4. Optimum temperature and pH determination
The relative hydrolyzing activity of Bb-TLE toward BAPNA as a
function of temperature was measured between 20 and 100 C. The
optimal temperature for the hydrolysis of the BAPNA peptide
substrate by Bb-TLE is reached at a temperature of approximately
40 C with an optimal temperature between 35 and 50 C (Fig. 6A).
At temperatures below 35 and above 60 C, its hydrolytic activity
decreased rapidly, demonstrating that Bb-TLE is heat labile.
Compared to these results, the enzyme exhibited optimal coagu-
lating activity at approx. 40 C, Fg coagulates in 60 min (Fig. 6B). On
the other hand, we have assessed the effect of pH between pH 2.0 to
10.0 on the hydrolyzing activity of Bb-TLE toward Fg, BAPNA and
coagulation of Fg in vitro. When human Fg was incubated with Bb-
TLE, the Aa chain was preferentially degraded with optimal activity
between pH 6.0 to 8.0 (Fig. 7A). No apparent alterations in Bb and g
chains in Fg molecule were observed, as shown by SDS-PAGE
(Fig. 7A). Furthermore, the relative amidolytic activity (compared
to maximum hydrolytic activity of BAPNA at pH 7.5) of Bb-TLE was
measured (Fig. 7B). Like the ﬁbrinogenolytic activity, the Bb-TLE
exhibits optimal hydrolysis of BAPNA between pH 6.0e8.0. In vitro,
coagulation of Fg by Bb-TLE shows a narrowed optimal pH (wpH
7.0) as shown in Fig. 7C. Coagulation of Fg by the venom enzyme
decreases dramatically at pH above 8 and below 5.
Fig. 3. Amino acid sequence comparison of barnettobin with snake venom serine proteinases and thrombin using CLUSTAL X Program. The numbering starts at the amino-terminal
amino acid of barnettobin (this work). Sequences were from the following sources: ancrod from A. rhodostoma (P26324); Bi-TLE from B. insularis (Q9DG83); crotalase from
C. adamanteus (F85114); leucurobin from B. leucurus (P0DJ86); batroxobin from B. atrox (P04971); TSV-PA from T. stejnegeri (Q91516); KN-BJ from B. jararaca (013069); halystase
from A. h. blomhofﬁi (P81176); BjussuSP I from B. jararacussu (Q2PQJ3); and thrombin (45). The catalytic triad residues (H40, D85, S179) are in gray, and the N-glycosylation sites are
in blue. Gaps have been introduced to optimize the sequence homology.
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substrates
The effect of several enzyme inhibitors on theBAPNAhydrolyzing
activity by Bb-TLE is summarized inTable 2. The enzyme activity was
inhibited (71%) by PMSF, a reagent for active-site serine residues of
serine proteases, functionally proving that the puriﬁed enzyme acts
as a serine-type protease. Its amidolytic activitywas also inhibited by
chymostatin, an inhibitor of serine and cysteine proteases (43%).
Other inhibitors of trypsin-like serine proteases SBTI and TLCK were
able to decrease the enzymatic activity (26 and 10%, respectively),
however, the enzyme was not affected by EDTA and heparin. The
rapid loss of activity (45%) promoted by the disulﬁde-reducing agent
DTT indicate the importance of disulﬁde bonds to the structural
integrity of the protease. Table 3, shows the hydrolyzing activity of
Bb-TLE toward various chromogenic substrates. The enzyme most
effectivelyhydrolyzed theamidase substrateBAPNA(55 timeshigher
than the crude venom). Also, the puriﬁed enzyme showed relatively
high activity toward TAME and chromozym TH (27 and 13 times
higher than the crude venom). In contrast, the plasmin substrate
S2251 (D-Val-Leu-Lys-pNA) with basic amino acid residue Lys in
place of Arg at P1 was not hydrolyzed by Bb-TLE.3.6. Enzymatic assays by deglycosylated Bb-TLE
With the aimof studying the role of the extensive glycosylation of
Bb-TLE a non-denaturing process was used to remove the N-linkedglycans. The effects of amidolytic activity bydeglycosylatedBb-TLE as
a function of time, pH and temperature are shown in Fig. 8, in com-
parison with the native enzyme. Hydrolysis of BAPNA by deglyco-
sylatedenzymedecreasedgraduallyafter several hours incubation to
about 55% at 72 h (Fig. 8A). Like these, deglycosylated enzyme retains
only 52% activity at optimal pH (pH 7) (Fig. 8B). Finally, 38% amido-
lytic activity of PNGase F-treated Bb-TLE was lost at optimal tem-
perature (40 C) as shown in Fig. 8C. These results indicate that N-
linked carbohydrate chains are important for in vitro activity of Bb-
TLE and may play an important role in the in vivo activity.3.7. Immunological assays
Next we investigated how puriﬁed rabbit anti-Bb-TLE IgG would
cross- react with related TLEs isolated from the pit viper venoms,
B. barnetti, B. atrox, B. leucurus, L. m. muta and C. d. terriﬁcus, to
experience its phylogenetic limits. Immunological cross-reactivity
was assessed by ELISA and western blotting. The antibody against
Bb-TLE reacted with highest intensity with Bb-TLE and with the
homologous enzymes from B. atrox and B. leucurus and with less
intensity with the enzymes of C. d. terriﬁcus and L. m. muta (Fig. 9).
Similar results were obtained from western blotting (not shown).3.8. 3D model of Bb-TLE and phylogenetic tree of serine proteases
The theoretical Bb-TLE 3D model was generated by knowledge-
based homology modeling (program PyMOL) using the
Fig. 4. Time course analysis of ﬁbrin(ogen)olytic activity of puriﬁed Bb-TLE on SDS-
PAGE (12% gel). A, Fg digestion; B, Fibrin digestion. Fg or ﬁbrin incubated with the
puriﬁed enzyme at 37 C for 15, 30, 60 and 120 min. C, Fg/ﬁbrin controls in the absence
of enzyme. Note that Bb-TLE shows speciﬁc cleavage on the a chains of both macro-
molecular substrates.
Fig. 5. Time-dependent elution proﬁles on RP-HPLC of peptides released from human
Fg by the action of Bb-TLE. A, standard peptides A and B as controls, and from BeD:
time dependent liberation of FPs. Details of conditions are given in the text.
Table 2
Effect of some inhibitors on amidolytic activity of barnettobin.
Inhibitor Concentration (mM) Residual activity (%)
None e 100
PMSF 5 29.4  1.5
DTT 5 55.7  3.0
SBTI 1 mg/ml 74.4  3.5
Chymostatin 50 mM 57.0  1.8
EDTA 5 100  5.0
TLCK 5 90  3.0
Heparin 5 U 100  5.0
The puriﬁed enzyme (1 mg) was pre-incubated with each compound at the indicated
concentrations in 1 ml of 50 mM Tris-HCl buffer, pH 8.0 at 37 C for 5 min, after
which 50 ml aliquots were taken to determine amidolytic activity on DL-BAPNA as
described under Materials and Methods. Controls were performed for each com-
pound (no inhibitor). Values are expressed as percentages relative to control and are
given as mean  S.D., n ¼ 4.
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meresurus stejnegeri (TSV-PA) as a template [22; PDB code 1BQY].
The overall structure of theoretical Bb-TLE shows the typical fold of
a trypsin-like serine proteases (Fig. 10) and thus belongs to the
trypsin/kallikrein gene family. For instance, the spatial organization
of the catalytic triad residues His40, Asp85, and Ser179 at the active
site cleft between the two subdomains of the b-barrel structure is
preserved as in the other SVSPs. Amino acid sequences of 20 SVSPs,
trypsin and thrombin were aligned and a tree was constructed by
using the programMEGA 4.1 (Fig. 11). The distance matrix was used
to reconstruct the tree by the neighbor-joining method [27] and
boot-strap estimates of the conﬁdence levels were conducted in
1000 replicates. Phylogenetic trees have been used to represent the
evolutionary past and the probability of common ancestry to
SVTLEs and other serine proteases [28]. Data in the literature
indicate that the amino acid sequences of venom gland serine
proteases have diversiﬁed in an accelerating manner [29]. Inaccordance with Wang et al. [28] and others, Fig. 11 shows the in-
dependent and parallel evolution of three major protease subtypes,
the coagulating enzymes (CLs), the kininogenases (KNs), and the
plasminogen activators (PAs). In spite of their great variety of
physiological properties, the SVSPs are composed of approx. 234
amino acids and are all highly homologous in sequence.4. Discussion
Venoms of South American pit vipers contain serine proteases
which exhibit ﬁbrin(ogeno)lytic activity and lead to spectacular
changes in hemostatic mechanism [3,6,30,31]. The present report
details the structural and biochemical characterization of the TLE
termed barnettobin to reﬂect its origin from B. barnetti venom. Bb-
TLE is a highly glycosylated protease that contains the catalytic
triad His40, Asp85 and Ser179 (barnettobin numbering) which is
the main criterion for classiﬁcation as a serine protease. The Mr
estimated by reduced SDS-PAGE was approx. 52 kDawhich reduces
to 28 kDa after treatment with N-Glycosidase. This difference in Mr
was expected because glycoproteins have an impaired capacity to
Table 3
Comparison of the hydrolyzing activities of barnettobin toward synthetic substrates.
Substrate Concentration (mM) Speciﬁc activity Ua/mg
Crude venom Barnettobin
TAME 2 4.64  0.9 118.8  3.5
BAEE 2 1.96  0.7 5.7  1.8
BAPNA 0.9 0.02  0.003 1.1  0.02
Chromozym TH 2 0.81  0.04 10.6  0.9
S-2251 0.8 0.00 0.01
a One unit was deﬁned as DA nm/min. Speciﬁc activity was expressed in U/mg.
These values are presented as mean S.D. (n ¼ 3).
Fig. 6. Effect of temperature on the amidolytic and coagulating activities of Bb-TLE. A,
amidolytic, and B, coagulating activities. Bb-TLE (1 mg) was assayed with BAPNA and Fg
at 20e100 C, respectively. Note that optimal activities were approx. at 40 C (at this
temperature, Fg coagulates in 60 s).
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trophoretic mobility [32]. Thus, the Mr of Bb-TLE (52 kDa),
compared with the Mrs of puriﬁed TLEs from, B. atrox (31.4 kDa),
B. leucurus (35 kDa), L. m. muta (41e47 kDa) and C. d. terriﬁcus
(32 kDa) measured by SDS-PAGE were obtained due to different
glycosylation levels (not shown). The carbohydrate content in
SVSPs varies considerably depending on the snake species and the
class of SVSPs, TLEs/coagulating (CLs), kininogenases (KNs) and
plasminogen activators (PAs) [28,33]. The Mr of native Bb-TLE
detected by mass spectrometry was 39,077.948. As mentioned
earlier mass spectrometric characterization of intact glycoproteins
is more difﬁcult than other simple spectrometric analysis of other
simple proteins due to the extensive microheterogeneity of the
carbohydrate moieties. Although MALDI-TOF/TOF mass spectrom-
etry is in principle capable of recording spectra of intact glyco-
proteins, resolution of individual glycoforms can only be achieved
for small proteins (w40 kDa). In addition, glycoproteins are less
efﬁciently ionized [32,34].
In addition to its clotting activity Bb-TLE catalyzed the hydrolysis
of the thrombin substrate chromozyn TH and was shown to have
esterase activity toward basic amino acid esters: TAME and BAEE.
However, it was inactive against the plasmin substrate S-2251
(Table 3) suggesting that arginine but not lysine is required at the
P1 site for substrate recognition. The fact that PMSF was able to
inhibit its esterase, amidolytic and clotting activities also identiﬁed
it as a serine protease. Furthermore, it appears that the same active
site is utilized by these functions. In accordance with studies on the
mechanism by which the TLEs Ancrod from Calloselasma rhodos-
toma (formerly Agkistrodon rhodostoma) [35] and batroxobin from
B. atrox [36] produce nonclotting blood suggest that these enzymes
produced an aberrant Fg which either (i) cannot be clotted by
thrombin or (ii) form microclots that are dispersed in the circula-
tion. It is assumed that Bb-TLE acts in the samemanner. In addition,
when the enzyme from B. barnettiwas incubated with Fg or plasma
(not shown) it immediately formed a ﬁbrin clot even in the pres-
ence of the anticoagulant heparin (Table 2).
The determined structure of the cDNA allowed the elucidation
of the complete amino acid sequence of Bb-TLE. Is N-terminal
sequence was conﬁrmed by automated amino acid sequencing that
also conﬁrmed the presence of a single amino-terminal residue
(Fig. 2). Analysis of the sequence alignment of Bb-TLE with other
SVSPs (Fig. 3), indicates remarkable conservation of the structural
features of the serine proteases including the twelve cysteineTable 4
Coagulant and deﬁbrinogenating effects of Bb-TLE.
Bb-TLE MCD-Fa (mg) MCD-Pa (mg) MDD-WBCb (mg/mouse)
Native 0.35 1.42 1.1
Deglycosylated NA NA NA
NA, no activity. These values are the average of two determinations in duplicate.
a MCD-F/P, minimum coagulant dose over ﬁbrinogen and human plasma.
b MDD-WBC, minimum deﬁbrinogenating dose-whole blood clotting.residues, and signiﬁcant elements of secondary structure (a-heli-
ces, b-strands and loops). Based on the homology with batroxobin
[36] (Fig. 3), and on the crystallographic structure of TSV-PA [37]
the six disulphide bridges of Bb-TLE appear to be Cys7-Cys138,
Cys25-Cys41, Cys73-Cys231, Cys117-Cys185, Cys149-Cys164, and
Cys175-Cys200. Residues Asp85, Asp173 and Asp179, which are
involved in the catalytic triad or in the formation of buried salt
bridges are highly conserved in Bb-TLE. Furthermore, residues
involved in the catalytic center are crucial for the speciﬁcity of these
proteases since their secondary structure, through their b-sheets
and a-helices, play an important role in their speciﬁcity, as
described for TSV-PA and batroxobin [37,38]. It has been reported
that phenylalanine 177 (Bb-TLE numbering) of TSV-PA plays a
crucial role in substrate and inhibition recognition and represents
one mechanism by which TSV-PA escapes from serpins [38], this
equivalent position is occupied by glycine in the majority of TLEs
(Fig. 3). In addition, experimental observations and theoretical data
indicated that the TLEs are not allosterically regulated by sodium
ions such as trypsin. This result was expected due to the conser-
vative proline at position 206 (this work) in that coagulant SVTLEs
group, instead of tyrosine presented in thrombin [39]. In the
theoretical Bb-TLE model, the potential N-glycosylation sites are
near the catalytic site and on three opposite loops (Fig. 10). This
prediction agrees with its biochemical properties, since it shows
that the carbohydrate in the structure may affect the activity of the
enzyme, interacting with the residues of the catalytic center and/or
with its surroundings [39,40]. Structural evidence for the function
of the carbohydrate in the SVSPs, AaV-SP-I and AaV-Sp-II from
Agkistrodon acutus has been reported earlier [41].
Fig. 7. Effect of pH on the activity of puriﬁed venom enzyme. A, ﬁbrinogenolytic; B,
amidolytic on DL-BAPNA; C, coagulant activity on citrated human plasma. The reaction
mixture was adjusted to the desired pH for 30 min at room temperature prior to
addition of enzyme (1 mg).
Fig. 8. Effect of Bb-TLE carbohydrate content on the susceptibility of the amidolytic
activity as a function of time (A), pH (B) and temperature (C). Results are presented as
S.D. (n ¼ 3), considering the amidolytic activity at 37 C, pH 7 of native or deglyco-
sylated enzymes as 100% activity. Native enzyme (50 mg) was deglycosylated by in-
cubation with 2 units of PNGase F as described in Materials and methods after which
the amidolytic activity on DL-BAPNAwas determined. Note that loss of N-glycosylation
affected the venom enzyme activity.
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that Bb-TLE has both ﬁbrinogenolytic and ﬁbrinolytic activities as
well as a deﬁbrinogenating effect in vivo, but speciﬁcally cleaved Fg
releasing FPA and its derivative (venombins A [7],) promoting
coagulation. Other venombin A enzymes capable of preferentially
releasing FPA from Fg include Arvin, batroxobin, leucurobin,
ancrod, the TLE from bushmaster and gyroxin [3]. It is known that
clots formed by TLEs are, therefore, soluble and not cross-linked
and are readily degraded by the ﬁbrinolytic system [11]. These
properties enable their clinical use as deﬁbrinogenating agents
[8,11,12,31]. In addition, like thrombin and other analogous SVTLEs
(bushmaster TLE, gyroxin, leucurobin), barnettobin produced axial
gyrations upon intravenous injection of mice at levels of 0.133 mg/g
mouse, perhaps due to the liberation of neuroactive peptides. The
gyroxin effect has been related to the clotting activity of a number
of SVTLEs and was elicited in mice by tail vein injection of puriﬁed
enzyme containing 0.25e0.75 NIH thrombin units of activity [42].
Because of its ﬁbrinogenolytic activity, barnettobin may be directly
involved in decreasing the levels of Fg in the plasma through
deﬁbrinogenation, and also reduces blood viscosity, improving
blood circulation as reported for other SVTLEs [5,10e12,43e45]. It is
known that deﬁbrinogenation is part of thrombolytic therapy. In
this regard, few TLEs have been successfully approved for clinical
use [3,11,12]. Ancrod (Viprinex) a venombin A from C. rhodostomais currently used for treating heparin-induced thrombocytopenia
and thrombosis [10,43e46]. Batroxobin (Deﬁbrase) another
enzyme from this group found in B. a. moogeni venom has been
indicated for treating acute cerebral infarction, angina pectoris and
sudden deafness [45]. Recent studies on the outcomes of clinical
trials assessing Ancrod in the treatment of acute ischemic stroke
[44] and other SVTLEs which are at different stages of clinical trials,
highlight the re-emerging interest in snake venom ﬁbrinogenases
as anti-thrombotics [45e47]. Desirable properties of some SVTLEs
include the increased selectivity for Fg in plasma, resistance to in-
hibition by endogenous thrombin inhibitors (serpins), and minimal
collateral effects e.g. bleeding. In this concept, a serine protease
termed Bothrops protease A (BPA) found in B. jararaca venom, is a
highly glycosylated protease (w62% carbohydrate content) showed
selective ﬁbrinogenolytic effect on human and rat plasma Fg [31].
Like BPA, barnettobin (52 kDa) is a glycoprotein (approx. 52%
Fig. 9. Reactivity of anti-Bb-TLE IgG against SVTLEs analyzed by indirect ELISA. 96-well
microtitration plates were precoated with 0.5 mg/well of puriﬁed: Bb-TLE (C),
batroxobin from B. atrox (;), leucurobin from B. leucurus (B), L. muta-TLE (6), C. d.
terriﬁcus-TLE (-). Anti- Bb-TLE IgG was added at different dilutions. Binding was
visualized by incubation with peroxidase-coupled anti-rabbit IgG (diluted 1:12,000)
and by further addition of o-phenylenediamine. The absorbance of preimmune serum
(control) was subtracted. Results are presented as S.D. (n ¼ 3).
Fig. 11. Phylogenetic tree of snake venom serine proteases. The computer program
Mega 4.1 and the amino acid sequences of 20 SVSPs, trypsin and thrombin so far
available were used to construct the tree. The enzyme abbreviations and references are
TLEs from L. muta muta (LM-TL), C. rhodostoma (ancrod, P26324), A. bilineatus (bili-
neobin, Q9PSN3), C. d. terriﬁcus (gyroxin, Q58G94), Trimeresurus stejnegeri (stejneﬁ-
brase-1, Q8AY80), B. barnetti (barnettobin, JX499027), B. insularis (Bi-TLE, Q9DG83),
B. leucurus (leucurobin, P0DJ86), B. atrox (batroxobin, P04971), B. alternatus (Bhalter-
nin, P0CG03), Gloydius blomhofﬁi (halystase, P81176), A. caliginosus (calobin, Q91053),
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in vitro and produced deﬁbrinogenating effects in mice. As
demonstrated in this study, the enzyme is insensitive to inhibition
by thrombin inhibitors e.g. heparin and serpins and only partially
inhibited by the serine protease inhibitors (PMSF, TLCK, SBTI)
probably due to its high carbohydrate content.
Conclusions. In the present study we have clariﬁed the structure
of the major coagulant TLE (barnettobin) of B. barnetti. ItsFig. 10. Theoretical Bb-TLE 3D model. The representation shows the secondary
structural features, with disulﬁde bridges in yellow, the catalytic triad His40, Asp85,
and Ser179 in red, the predicted N-glycosylation sites (Asn129, Asn145, and Asn226) in
blue spheres. The b/b hydrolase fold typical of serine proteases from the chymotrypsin
family and the C-terminal extension characteristic of SVSPs is indicated. Model was
generated by the Pymol program [48].
B. jararaca (KN-BJ, O13069), C. adamanteus (crotalase, F85114), L. m. muta plasminogen
activator (LV-PA, Q27J47), T. stejnegeri (TSV-PA, Q91516), A. halys (Haly-PA, AF017736),
Protobothrops ﬂavoviridis (ﬂavoxobin, P05620), B. jararacussu (BjussuSP-I, ABC24687),
B. jararaca (bothrombin, P81661), trypsin and thrombin [49].carbohydrate content w52% plays an important role in the struc-
ture and activity of this glycosylated enzyme. Since the protease
selectively targets ﬁbrinogen and ﬁbrin in vitro and showed
deﬁbrinogenating effect in in vivo models, it indeed suggests that
there may be great potential in exploiting this novel ﬁbrinogeno-
lytic enzyme as anti-thrombotic agent.Conﬂict of interest
The authors declared there is not conﬂict of interest.Acknowledgments
This work was supported by grants of the Brazilian agencies
CNPq and FAPEMIG (CBB APQ 01791-10 to EFS); Vice Rectorado de
Investigación, y Consejo de Investigaciones, Universidad Nacional
Mayor de San Marcos (Lima-Perú). We thank the PhD student E.G.
Koslova for his help in prepare the 3D model. EFS was supported by
research fellowship from CNPq. This report is part of a dissertation
for Ms degree of DVR to Post Graduate School in Biological Sciences,
National University of San Marcos.References
[1] S. Braud, C. Bon, A. Wisner, Snake venom proteins acting on hemostasis,
Biochimie 82 (2000) 851e859.
D.E. Vivas-Ruiz et al. / Biochimie 95 (2013) 1476e14861486[2] N. Rawlings, A.J. Barrett, Introduction: serine peptidases and their clans, in:
N. Rawlings, A.J. Barrett, J.F. Woessner (Eds.), Handbook of Proteolytic En-
zymes, second ed., Elsevier Academic Press, 2004, pp. 1417e1439.
[3] D.J. Phillips, S.D. Swenson, F.S. Markland, Thrombin-like snake venom serine
proteinases, in: S.P. Mackessy (Ed.), Handbook of Venoms and Toxins of
Reptiles, CRC Press, New York, London, 2010, pp. 139e152.
[4] K. Stocker, Snake venom proteins affecting hemostasis and ﬁbrinolysis, in:
K.F. Stocker (Ed.), Medical Use of Snake Venom Proteins, CRC Press Inc., Boca
Raton, FL, 1990, pp. 97e160.
[5] N.A. Marsh, Snake venoms affecting the haemostatic mechanism e a consid-
eration of their mechanisms, practical applications and biological signiﬁcance,
Blood Coagul. Fibrinolysis 5 (1994) 399e410.
[6] E.F. Sanchez, Snake venom proteinases that affect coagulation and ﬁbrinolysis,
in: M.E. De Lima, A.M.C. Pimenta, M.F. Martin-Eauclaire, R.B. Zingali, H. Rochat
(Eds.), Animal Toxins: State of the Art Perspectives in Health and Biotech-
nology, Editora UFMG, Belo Horizonte, Brazil, 2009, pp. 575e588.
[7] F.S. Markland, Snake venoms and the hemostatic system, Toxicon 36 (1998)
1749e1800.
[8] R.M. Kini, Toxins in thrombosis and haemostasis: potential beyond imagina-
tion, J. Thromb. Haemost. 9 (2011) 193e208.
[9] A. Polgár, Catalytic mechanisms of serine and threonine peptidases, in:
N. Rawlings, A.J. Barrett, J.F. Woessner (Eds.), Handbook of Proteolytic En-
zymes, second ed., Elsevier Academic Press, 2004, pp. 1440e1448.
[10] W.R. Bell Jr., Deﬁbrinogenating enzymes, Drugs 54 (1997) 18e30.
[11] N. Marsh, V. Williams, Practical applications of snake venom toxins in hae-
mostasis, Toxicon 45 (2005) 1171e1181.
[12] T. Sajevic, A. Leonardi, I. Krizaj, Haemostatically active proteins in snake
venoms, Toxicon 57 (2011) 627e645.
[13] J.A. Campbell, W.W. Lamar, The Venomous Reptiles of the Western Hemi-
sphere, Comstock Publishing Associates, Ithaca, New York, 2004.
[14] A. Zavaleta, M. Salas, Oﬁdismo: envenenamiento por mordeduras de ser-
pientes, in: J.R. Martinez-Villaverde, E. Leon Barua, L. Vidal-Neira, R. Losno-
Garcia (Eds.), Emergencias en medicina interna, 1966, pp. 241e260. Lima,
Perú.
[15] M. Kohlhoff, M.H. Borges, A. Yarleque, C. Cabezas, M. Richardson, E.F. Sanchez,
Exploring the proteomes of the venoms of the Peruvian pit vipers Bothrops
atrox, B. barnetti and B. pictus, J. Proteomics 75 (2012) 2181e2195.
[16] G.B. Naumann, L.F. Silva, L. Silva, G. Faria, M. Richardson, K. Evangelista,
M. Kohlhoff, C.M.F. Gontijo, A. Navdaev, F.F. Rezende, J.A. Eble, E.F. Sanchez,
Cytotoxicity and inhibition of platelet aggregation caused by an l-amino acid
oxidase from Bothrops leucurus venom, Biochim. Biophys. Acta 1810 (2011)
683e694.
[17] A. Magalhaes, H.P.B. Magalhaes, M. Richardson, S. Gontijo, R.N. Ferreira,
A.P. Almeida, E.F. Sanchez, Puriﬁcation and properties of a coagulant
thrombin-like enzyme from the venom of Bothrops leucurus, Comp. Biochem.
Physiol. A 146 (2007) 565e575.
[18] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head
of bacteriophage T4, Nature 227 (1970) 680e685.
[19] F.P. Silva-Junior, H.L.M. Guedes, L.C. Garvey, A.S. Aguiar, S.C. Bourguignon,
E.D. Cera, S.G. De-Simione, BJ-48, a novel thrombin-like enzyme from the
Bothrops jararacussu venomwith high selectivity for Arg over Lys in P1: role of
N-glycosylation in termostability and active site accessibility, Toxicon 50
(2007) 18e31.
[20] R.D.G. Theakston, H.A. Reid, Development of simple standard assay pro-
cedures for the characterization of snake venoms, Bull. World Health Organ.
61 (1983) 949e956.
[21] M.-I. Estevão-Costa, C.R. Diniz, A. Magalhães, F.S. Markland, E.F. Sanchez, Ac-
tion of metalloproteinases mutalysin I and II on several components of the
hemostatic system, Thromb. Res. 99 (2000) 363e373.
[22] M.A.A. Parry, U. Jacob, R. Hubert, A. Wisner, C. Bon, W. Bode, The crystal
structure of the novel snake venom plasminogen activator TSV-PA: a proto-
type structure for snake venom serine proteinases, Structure 6 (1998) 1195e
1206.
[23] P. Friberger, Chromogenic peptide substrates. Their use for the assay of factors
in the ﬁbrinolytic and the plasma kallikreinekinin systems, Scand. J. Clin. Lab.
Invest. 42 (162) (1982) 15e47.
[24] G. Schmert, Y. Takenaka, A spectrophotometric determination of trypsin and
chymotrypsin, Biochim. Biophys. Acta 16 (1955) 570e575.
[25] E.F. Sanchez, C.I. Santos, A. Magalhães, C.R. Diniz, S. Figueiredo, J. Gilroy,
M. Richardson, Isolation of a proteinase with plaminogen activating activity
from Lachesis muta muta (bushmaster) snake venom, Arch. Biochem. Biophys.
378 (2000) 131e141.
[26] K.L. Jimenez, A.I. Zavaleta, V. Izaguirre, A. Yarleque, R.S. Inga, Clonaje y car-
acterización molecular in silico de un transcrito de fosfolipase A2, aislado delveneno de la serpiente Peruana Lachesis muta muta, Rev. Peru. Med. Exp. Salud
Publica 27 (2010) 532e539.
[27] N. Saitou, M. Nei, The neighbor-joining method: a new method for recon-
structing phylogenetic trees, Mol. Biol. Evol. 4 (1987) 406e425.
[28] Y.-M. Wang, S.-R. Wang, I.-H. Tsai, Serine protease isoforms of Deinagkistrodon
acutus venom: cloning, sequencing and phylogenetic analysis, Biochem. J. 354
(2001) 161e168.
[29] M. Deshimaru, T. Ogawa, K. Nakashima, I. Nobuhisa, T. Chijiwa,
Y. Shimohigashi, Y. Fukumaki, M. Niwa, I. Yamashina, S. Hattori, M. Ohno,
Accelerated evolution of crotalinae snake venom gland serine proteases, FEBS
Lett. 397 (1996) 83e88.
[30] E.F. Sanchez, S. Swenson, Proteases from South American snake venoms
affecting ﬁbrinolysis, Curr. Pharm. Anal. 3 (2007) 147e157.
[31] A.F. Paes Leme, B.C. Prezoto, E.T. Yamashiro, L. Bertolim, A.K. Tashima,
C.F. Klitzke, A.C.M. Camargo, S.M.T. Serrano, Bothrops protease A, a unique
highly glycosylated serine proteinase, is a potent, speciﬁc ﬁbrinogenolytic
agent, J. Thromb. Haemost. 6 (2008) 1363e1372.
[32] R. Pitt-Rivers, F.S.A. Impiombato, The binding of sodium dodecyl sulfate to
various proteins, Biochem. J. 109 (1968) 825e830.
[33] E.F. Sanchez, L.F. Felicori, C. Chavez-Olortegui, H.B.P. Magalhaes,
A.L. Hermogenes, M.V. Diniz, I.L.M. Junqueira-de-Azevedo, A. Magalhaes,
M. Richardson, Biochemical characterization and molecular cloning of a
plasminogen activator proteinase (LV-PA) from bushmaster snake venom,
Biochim. Biophys. Acta 1760 (2006) 1762e1771.
[34] H. Geyer, R. Geyer, Strategies for analysis of glycoprotein glycosylation, Bio-
chim. Biophys. Acta 1764 (2006) 1853e1869.
[35] L.C. Au, S.B. Lin, J.S. Chou, G.W. Teh, K.J. Chang, C.M. Shih, Molecular cloning
and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from
the venom of Calloselasma rhodostoma, Biochem. J. 294 (1993) 387e390.
[36] N. Itoh, N. Tanaka, S. Mihashi, I. Yamashina, Molecular cloning and sequence
analysis of cDNA for batroxobin, a thrombin-like venom enzyme, J. Biol. Chem.
262 (1987) 3132e3135.
[37] S. Braud, M.A. Parry, R. Maroun, C. Bon, A. Wisner, The contribution of residues
192 and 193 to the speciﬁcity of snake venom serine proteinases, J. Biol.
Chem. 275 (2000) 1823e1828.
[38] S. Braud, B.F. Le Bonniec, C. Bon, A. Wisner, The stratagem utilized by the
plasminogen activator from the snake Trimeresurus stejnegeri to escape ser-
pins, Biochemistry 41 (2002) 8478e8484.
[39] C.D. Sant`Ana, C.P. Bernardes, L.F.M. Isidoro, M.V. Mazzi, S.G. Soares, A.L. Fuly,
R.B. Zingali, R.G. Stabeli, S.V. Sampaio, A.M. Soares, Molecular characterization
of BjussuSP-I, a new thrombin-like enzyme with procoagulant and kallikrein-
like activity isolated from Bothrops jararacussu snake venom, Biochimie 90
(2008) 500e507.
[40] H.C. Castro, R.B. Zingali, M.G. Alburquerque, M. Pujol-Luz, C.R. Rodrigues,
Snake venom thrombin-like enzymes: from reptilase to now, Cell. Mol. Life
Sci. 61 (2004) 843e856.
[41] Z. Zhu, Z. Liang, T. Zhang, Z. Zhu, W. Xu, M. Teng, L. Niu, Crystal structures and
amidolytic activities of two glycosylated snake venom serine proteinases,
J. Biol. Chem. 280 (2005) 10524e10529.
[42] G. Alexander, J. Grothusen, H. Zepeda, R.J. Schwartzman, Gyroxin, a toxin from
the venom of the Crotalus durissus terriﬁcus, is a thrombin-like enzyme,
Toxicon 26 (1988) 953e960.
[43] D.E. Levy, G.J. Del Zoppo, Ancrod: a potential treatment for acute ischemic
stroke from snake venom, Toxicol. Rev. 25 (2006) 323e333.
[44] M.G. Hennerici, R. Kay, J. Bogousslavsky, G.L. Lenzi, M. Verstraete,
J.M. Orgogozo, Intravenous ancrod for acute ischemic stroke in the European
stroke treatment with ancrod trial: a randomized controlled trial, Lancet 368
(2006) 1871e1878.
[45] J.W. Fox, S.M. Serrano, Approaching the golden age of natural product phar-
maceuticals from venom libraries: an overview of toxin-derivatives currently
involved in therapeutic or diagnostic applications, Curr. Pharm. Des. 13 (2007)
2927e2934.
[46] D.G. Sherman, R.P. Atkinson, T. Chippendale, K.A. Levin, K. Ng, N. Futrell,
C.Y. Hsu, D.E. Levy, Intravenous ancrod for treatment of acute ischemic stroke:
the STAT study: a randomized controlled trial. Stroke treatment with ancrod
trial, J. Am. Med. Assoc. 283 (2000) 2395e2403.
[47] E.E. Gardiner, R.K. Andrews, The cut of the clot (h): snake venom ﬁbrinoge-
nases as therapeutic agents, J. Thromb. Haemost. 6 (2008) 1360e1362.
[48] W.S. Delano, The PyMOL Molecular Graphics System, Delano Scientiﬁc, San
Carlos, CA, 2002. http://www.pymol.org.
[49] W. Bode, D. Turk, A. Karshikov, The reﬁned 1.9-Å-X-ray crystal structure of D-
Phe-Pro-Arg chloromethylcetone-inhibited human [a]-thrombin: structure
analysis, overall structure, electrostatic properties, detailed active-site ge-
ometry, and structure-function relationship, Protein Sci. 1 (1992) 426e471.
